Wasatch Advisors LP Trims Stake in Artivion, Inc. (NYSE:AORT)

Wasatch Advisors LP lowered its position in Artivion, Inc. (NYSE:AORT) by 11.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 815,832 shares of the company’s stock after selling 105,717 shares during the quarter. Wasatch Advisors LP’s holdings in Artivion were worth $21,717,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in AORT. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Artivion by 58.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock worth $9,074,000 after buying an additional 125,668 shares during the period. Perceptive Advisors LLC increased its stake in Artivion by 4.7% in the 2nd quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock worth $71,658,000 after buying an additional 124,725 shares during the period. Sio Capital Management LLC purchased a new position in Artivion in the 3rd quarter worth about $3,226,000. Walleye Capital LLC purchased a new position in Artivion in the 3rd quarter worth about $960,000. Finally, Vanguard Group Inc. increased its stake in Artivion by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock worth $56,388,000 after buying an additional 33,982 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Amy Horton sold 12,430 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total value of $325,417.40. Following the sale, the chief accounting officer now directly owns 139,989 shares in the company, valued at approximately $3,664,912.02. This trade represents a 8.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts recently commented on AORT shares. Stifel Nicolaus raised their price target on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, September 13th. Oppenheimer raised their price target on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. JMP Securities assumed coverage on shares of Artivion in a report on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 target price on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $30.00 target price on shares of Artivion in a report on Friday, September 27th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $31.00.

Artivion Stock Up 1.6 %

Shares of Artivion stock opened at $29.52 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. Artivion, Inc. has a 1 year low of $16.48 and a 1 year high of $30.00. The firm’s 50-day moving average is $27.00 and its two-hundred day moving average is $25.81. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -1,476.00 and a beta of 1.75.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.